Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Not yet recruiting · NCT07539779 · Registry updated 2026-04-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm, primary myelofibrosis | Not yet recruiting | Phase 2 / Phase 3 | 2026-04-20 | NCT07539779 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nanfang Hospital, Southern Medical University | 248 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Nanfang Hospital, Southern Medical University | Guangzhou | China | 83 |